CoreCap Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
AIM
FWIA
DLA
ETC
CoreCap Advisors's BMY Position: Q2 2026 in Review
CoreCap Advisors increased its Bristol-Myers Squibb (BMY) stake by 4.4% in Q2 2026, buying an estimated $59.6K and bringing the position to 24,801 shares worth $1.43M. The position accounts for 0.04% of the portfolio, ranked #309.
CoreCap Advisors first reported a position in BMY in Q4 2021 and has held it in 17 quarters since. The position peaked at $1.73M in Q4 2022. 879 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- CoreCap Advisors held 24,801 shares of Bristol-Myers Squibb worth $1.43M as of Q2 2026.
- CoreCap Advisors bought 1,038 Bristol-Myers Squibb shares in Q2 2026, an estimated $59.6K.
- Bristol-Myers Squibb made up 0.04% of CoreCap Advisors's portfolio in Q2 2026, its #309 holding.
- CoreCap Advisors first reported a position in Bristol-Myers Squibb in Q4 2021 and has held it in 17 quarters since.
- CoreCap Advisors's Bristol-Myers Squibb position peaked at $1.73M in Q4 2022.
- 879 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.